rroodd
IMO
Agree multiple drugs in pipeline is essential
Buying GDC0084 from Genentech and being responsible for all expenditure since 2016 was never going to work for a nano biotech
Current situation
Cantrixil requires a partner and GDC0084 requires up to $20m for phase 11b alone
After Anisina failed they were left with Cantrixil only and imo had no choice in buying a drug that is well beyond their capabilities financially
Look at the facts - The price at the reverse split was 40c and today years on the highest bid is 39c
DYOR
- Forums
- ASX - By Stock
- KZA
- KZA Media Thread
KZA Media Thread, page-123
-
-
- There are more pages in this discussion • 1,944 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity